eric
11-30-2005, 09:08 AM
http://today.reuters.com/business/newsarticle.aspx?type=health&storyID=nFAB009756&imageid=&cap=
FRANKFURT, Nov 30 (Reuters) - German drugmaker Schering (SCHG.DE: Quote (http://today.reuters.com/stocks/overview.aspx?symbol=SCHG.DE), Profile (http://today.reuters.com/stocks/CompanyProfile.aspx?symbol=SCHG.DE), Research (http://today.reuters.com/stocks/ResearchReports.aspx?symbol=SCHG.DE)) on Wednesday announced the start of three mid-stage, or Phase II, trials on anti-cancer drug ZK-EPO.
The Berlin-based group said the drug would be tested for several types of cancer such as non small-cell lung cancer, ovarian cancer and breast cancer.
The non-small cell lung cancer trial is currently enrolling patients in Germany, and will examine the safety and efficacy of ZK-EPO in patients with advanced disease.
"The Phase I data leads us to believe ZK-EPO has potential to become an important new anti-cancer therapy to treat people with a variety of solid tumours," Carlo Montagner, head of oncology at Schering group said.
© Reuters 2005. All Rights Reserved.
FRANKFURT, Nov 30 (Reuters) - German drugmaker Schering (SCHG.DE: Quote (http://today.reuters.com/stocks/overview.aspx?symbol=SCHG.DE), Profile (http://today.reuters.com/stocks/CompanyProfile.aspx?symbol=SCHG.DE), Research (http://today.reuters.com/stocks/ResearchReports.aspx?symbol=SCHG.DE)) on Wednesday announced the start of three mid-stage, or Phase II, trials on anti-cancer drug ZK-EPO.
The Berlin-based group said the drug would be tested for several types of cancer such as non small-cell lung cancer, ovarian cancer and breast cancer.
The non-small cell lung cancer trial is currently enrolling patients in Germany, and will examine the safety and efficacy of ZK-EPO in patients with advanced disease.
"The Phase I data leads us to believe ZK-EPO has potential to become an important new anti-cancer therapy to treat people with a variety of solid tumours," Carlo Montagner, head of oncology at Schering group said.
© Reuters 2005. All Rights Reserved.